title: Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)
author: James H. Finke
description: "...good reading for all those interested in oncological immunotherapy." -Cancer Forum<br /> <br /> "State of the art and insightful...illuminates the possibilities for developing effective immunotherapies that can block the mechanisms by which tumors evade the immune system in different histologic types of tumors." - Tumori
zlib_text: CYCLOSPORIN A
  CAS No. 59865-13-3
  First Listed in the Eighth Report on Carcinogens
  CARCINOGENICITY
  Cyclosporin A is known to be a human carcinogen based on studies in humans
  indicating a causal relationship between exposure to cyclosporin A and human cancer
  (IARC 1990).
  Numerous case reports (IARC 1990) describe cancer (mainly lymphoma or skin
  cancer) developing in organ transplant recipients, psoriasis patients, and rheumatoid
  arthritis patients treated with cyclosporin A for immunosuppression.  Some of these
  patients were treated with cyclosporin A alone, whereas others were treated with other
  immunosuppressive agents in combination with cyclosporin A.  The time between
  treatment initiation and tumor development ranged from 1 month to 10 years.  In some
  cases, tumors regress after discontinuation of treatment with cyclosporin A.  Several
  cohort studies also indicate that cyclosporin A is carcinogenic in humans, inducing a
  tumor incidence of less than 5% in the patient population (IARC